Current treatment and recent therapeutic developments in TNBC
We are delighted to invite you to a webinar exploring the evolving treatment landscape of metastatic triple negative breast cancer (mTNBC). Dr Mark Harries, Consultant Medical Oncologist at Guy’s and St Thomas’ in London will discuss the current and evolving treatment landscape of TNBC and introducing the newly approved antibody-drug conjugate (ADC), the first-in-class ADC that targets TROP-2, a commonly expressed marker in TNBC.
October 5, 2022 | 12:15 – 12:55 (CEST) SE-TRO-0060
